S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

$11.08
-0.37 (-3.23%)
(As of 03/28/2024 ET)
Today's Range
$11.06
$11.51
50-Day Range
$8.53
$12.29
52-Week Range
$5.22
$12.50
Volume
1.61 million shs
Average Volume
1.06 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.10

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.2% Upside
$11.10 Price Target
Short Interest
Healthy
4.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Cellebrite DI in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.13%
From $0.32 to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

Business Services Sector

266th out of 311 stocks

Prepackaged Software Industry

182nd out of 197 stocks

CLBT stock logo

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Cellebrite Pathfinder helps investigators reach conclusions faster through automated data ingestion, normalization, consolidation, and visualization of a suspects' journey; CryptoCurrency Investigative Solutions, which analyze blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets and transactions; and OSINT Investigate solution used to search, resolve, and enrich identifiers in open sources. In addition, the company provides Cellebrite Guardian, a cloud-based digital investigative data and evidence management SaaS solution that allows users to manage, store, share, and review investigative data and evidence from intake to creation of a final report; and Commander solution that enables collaboration across investigation functions to reduce manual processes. It serves federal and state and local agencies, as well as enterprise companies and service providers. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. is a subsidiary of Sun Corporation.

CLBT Stock Price History

CLBT Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Cellebrite Files its 2023 Annual Report on Form 20-F
Cellebrite Files its 2023 Annual Report on Form 20-F
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
UPDATE – Cellebrite Announces 2024 Investor Day
Cellebrite Announces 2024 Investor Day
William Blair Keeps Their Hold Rating on Cellebrite DI (CLBT)
Cellebrite (CLBT) Benefitting from Increased Data Volume
See More Headlines
Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:CLBT
Employees
1,005
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.10
High Stock Price Target
$13.50
Low Stock Price Target
$9.00
Potential Upside/Downside
-0.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,100,000.00
Pretax Margin
-23.24%

Debt

Sales & Book Value

Annual Sales
$325.11 million
Cash Flow
$0.25 per share
Book Value
$0.18 per share

Miscellaneous

Free Float
193,595,000
Market Cap
$2.27 billion
Optionable
Optionable
Beta
1.56
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Yossi Carmil (Age 56)
    Founder, CEO & Director
    Comp: $946k
  • Ms. Dana Gerner (Age 57)
    Chief Financial Officer
    Comp: $477k
  • Mr. Leeor Ben-Peretz (Age 48)
    Chief Strategy Officer
    Comp: $416k
  • Mr. Marque Teegardin (Age 58)
    President of Cellebrite Americas - Sales Management
    Comp: $868.71k
  • Mr. Thomas E. Hogan (Age 65)
    Executive Chairman
  • Mr. Arnon Zilberman
    Executive Vice President of Information Systems & Operations
  • Mr. Ronnen Armon (Age 61)
    Chief Products & Technologies Officer
  • Andrew Kramer
    Vice President of Investor Relations
  • Ms. Ayala Berler Shapira
    General Counsel
  • Ms. Lisa Cole (Age 50)
    Chief Marketing Officer

CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings
or view top-rated stocks.

What is Cellebrite DI's stock price target for 2024?

5 analysts have issued twelve-month target prices for Cellebrite DI's shares. Their CLBT share price targets range from $9.00 to $13.50. On average, they expect the company's share price to reach $11.10 in the next year. This suggests a possible upside of 0.2% from the stock's current price.
View analysts price targets for CLBT
or view top-rated stocks among Wall Street analysts.

How have CLBT shares performed in 2024?

Cellebrite DI's stock was trading at $8.66 on January 1st, 2024. Since then, CLBT shares have increased by 27.9% and is now trading at $11.08.
View the best growth stocks for 2024 here
.

Are investors shorting Cellebrite DI?

Cellebrite DI saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,620,000 shares, an increase of 11.5% from the February 29th total of 2,350,000 shares. Based on an average daily trading volume, of 978,000 shares, the short-interest ratio is presently 2.7 days. Currently, 4.7% of the company's stock are sold short.
View Cellebrite DI's Short Interest
.

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CLBT earnings forecast
.

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) posted its earnings results on Thursday, February, 15th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.02. The firm had revenue of $93.01 million for the quarter, compared to analyst estimates of $85.43 million. Cellebrite DI had a positive trailing twelve-month return on equity of 173.14% and a negative net margin of 24.94%.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).

What guidance has Cellebrite DI issued on next quarter's earnings?

Cellebrite DI updated its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by many different retail and institutional investors. Top institutional shareholders include IGP Investments G.P.L.P LP (11.18%), Clal Insurance Enterprises Holdings Ltd (3.76%), Crosslink Capital Inc. (1.72%), Greenhaven Road Investment Management L.P. (1.52%), Voss Capital LLC (0.97%) and Ashford Capital Management Inc. (0.79%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners